How recognizing the unique characteristics of each patient optimizes resources and maximizes impact Medication non-adherence is an age-old problem that pharmaceutical companies have been grappling with for decades. According to industry research, the global pharmaceutical industry loses…
Read more
AllazoHealth CEO Clifford Jones and Chief Operating Officer William Grambley recently answered questions about patient intervention data: what it is, how clients employ it, and how AllazoHealth uses this data to accurately predict individual patient…
Read more
Medication non-adherence continues to be one of the most widespread issues faced by the pharmaceutical industry. According to the U.S. Centers for Disease Control, approximately 50 percent of people with chronic illnesses stop taking their…
Read more
Eli Lilly and Co. and Abbott have made headlines recently for using real-world evidence to prove better adherence and outcomes for its diabetes products. More pharma companies are likely to utilize real-world data to support…
Read more
With medication non-adherence costing the industry more than $600 billion a year, many pharmaceutical companies are creating medication adherence programs, often in conjunction with pharmacists and payers. According to Andrea Kasprzyk, Director of Sales at…
Read more
A leading pharmaceutical company engaged AllazoHealth on a multi-year project using artificial intelligence to optimize a patient support program for a major product. Overcoming an adherence challenge The pharmaceutical company faced a challenge: An estimated…
Read more